• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • COVID-19
  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • Artificial Intelligence
    • Blockchain
    • Mobile Health
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

IBM, KPMG, Merck and Walmart to Launch FDA Blockchain Pilot Program

by Fred Pennic 06/13/2019 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

FDA Approves Blockchain/IoT Pilot to Track Specialty Prescription Drugs Across 3 States Blockchain in Healthcare_Next Stop for Data-driven Healthcare: Blockchain

IBM, KPMG, Merck, and Walmart today announced that the companies have been selected by the United States Food and Drug Administration (FDA) to be included in a blockchain pilot program in support of the U.S. Drug Supply Chain Security Act (DSCSA) that addresses requirements to identify, track and trace prescription medicines and vaccines distributed within the United States.

Pilot Program Overview

The FDA pilot program is intended to evaluate the use of blockchain technology to assist drug supply chain stakeholders, including FDA, in developing the electronic, interoperable system that will identify and trace certain prescription drugs as they are distributed within the United States. Blockchain is designed to establish a permanent record and may be integrated with existing supply chain and traceability systems.

The FDA selected IBM, KPMG, and Walmart based on their extensive experience in implementing blockchain solutions to help enhance the safety and traceability of products. Increasingly, customers are requesting more detailed information about products. Each company will create a shared permissioned blockchain network that allows real-time monitoring of products. The proposed network is intended to help reduce the time needed to track and trace inventory; allow timely retrieval of reliable distribution information; increase accuracy of data shared among network members, and help determine the integrity of products in the distribution chain, including whether products are kept at the correct temperature.

Pilot Program Launch Date

The pilot project is scheduled to be completed in the fourth quarter of 2019, and results are expected to be published in an FDA DSCSA program report. At that time, the project’s participants will evaluate next steps.

Why It Matters

“With successful Blockchain pilots in pork, mangoes and leafy greens that provide enhanced traceability, we are looking forward to the same success and transparency in the biopharmaceutical supply chain” said Karim Bennis, Walmart’s Vice President of Strategic Planning and Implementation, Health and Wellness. “We believe we have to go further than offering great products that help our customers live better at everyday low prices. Our customers also need to know they can trust us to help ensure products are safe. This pilot and U.S. Drug Supply Chain Security Act requirements will help us do just that.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: biopharmaceutical, blockchain, Blockchain Technology, FDA, Healthcare Blockchain, IBM, integrity, KPMG, Walmart

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Knowledge Hub

 How Top Health Plans Use AI to Save Money and Work Smarter How Top Health Plans Use AI to Save Money and Work Smarter

 How to Build Hybrid Care Models Around Remote Patient Monitoring How to Build Hybrid Care Models Around Remote Patient Monitoring

Trending

Olive Secures $400M At A $4B Valuation to Support New Instant Claim Payment Solution

Olive Shutters Business After Sale to Waystar and Humata Health

Clinician Shortage Worsens Primary Care Crisis, Experts Reveal

Clinician Shortage Worsens Primary Care Crisis, Experts Reveal

FDA Grants Clearance for UltraSight's AI Cardiac Ultrasound

Israel Defense Forces to Utilize UltraSight’s PoCUS Devices in Combat

The Future of Biomarker-Based Therapy for Mental Disorder Care

The Future of Biomarker-Based Therapy for Mental Disorder Care

HLTH23: 6 Digital Health Executives Share Key Takeaways

6 Digital Health Executives Share Key Takeaways from HLTH23

HIMSS Appoints New Chief Financial Officer & General Counsel

HIMSS Appoints New Chief Financial Officer & General Counsel

GoodRx Now Offers Access to $35 Insulin to All Americans

GoodRx Now Offers Access to $35 Insulin to All Americans

Ozempic: From Diabetes Management to Potential Weight Loss Miracle

Ozempic: From Diabetes Management to Potential Weight Loss Miracle

Health M&A: Financial Distress Driving Q3 Healthcare Deals

Health M&A: Financial Distress Driving Q3 Healthcare Deals

GE HealthCare Inks $44M Contract with BARDA to Develop AI-Driven Ultrasound Tech

GE HealthCare Inks $44M Contract with BARDA to Develop AI-Driven Ultrasound Tech

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • 2023 Editorial Calendar
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2023. HIT Consultant Media. All Rights Reserved. Privacy Policy |